AMGN vs. THC: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at AMGN and THC, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | AMGN | THC |
|---|---|---|
| Company Name | Amgen Inc. | Tenet Healthcare Corporation |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Health Care Providers & Services |
| Market Capitalization | 155.03 billion USD | 16.08 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | June 17, 1983 | March 17, 1980 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of AMGN and THC by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | AMGN | THC |
|---|---|---|
| 5-Day Price Return | -2.63% | 2.57% |
| 13-Week Price Return | 3.05% | 10.21% |
| 26-Week Price Return | -4.96% | 40.39% |
| 52-Week Price Return | -11.88% | 11.16% |
| Month-to-Date Return | -2.42% | 12.82% |
| Year-to-Date Return | 10.49% | 44.14% |
| 10-Day Avg. Volume | 1.78M | 1.00M |
| 3-Month Avg. Volume | 2.47M | 1.54M |
| 3-Month Volatility | 26.11% | 36.54% |
| Beta | 0.49 | 1.53 |
Profitability
Return on Equity (TTM)
AMGN
97.92%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
AMGN’s Return on Equity of 97.92% is exceptionally high, placing it well beyond the typical range for the Biotechnology industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
THC
37.25%
Health Care Providers & Services Industry
- Max
- 26.03%
- Q3
- 13.74%
- Median
- 8.26%
- Q1
- 4.13%
- Min
- -3.62%
THC’s Return on Equity of 37.25% is exceptionally high, placing it well beyond the typical range for the Health Care Providers & Services industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Net Profit Margin (TTM)
AMGN
18.96%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
A Net Profit Margin of 18.96% places AMGN in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
THC
7.17%
Health Care Providers & Services Industry
- Max
- 12.40%
- Q3
- 5.93%
- Median
- 1.96%
- Q1
- 0.93%
- Min
- -6.10%
A Net Profit Margin of 7.17% places THC in the upper quartile for the Health Care Providers & Services industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
AMGN
24.01%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
An Operating Profit Margin of 24.01% places AMGN in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
THC
17.77%
Health Care Providers & Services Industry
- Max
- 19.05%
- Q3
- 10.21%
- Median
- 4.22%
- Q1
- 1.98%
- Min
- -4.27%
An Operating Profit Margin of 17.77% places THC in the upper quartile for the Health Care Providers & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | AMGN | THC |
|---|---|---|
| Return on Equity (TTM) | 97.92% | 37.25% |
| Return on Assets (TTM) | 7.35% | 5.11% |
| Net Profit Margin (TTM) | 18.96% | 7.17% |
| Operating Profit Margin (TTM) | 24.01% | 17.77% |
| Gross Profit Margin (TTM) | 69.71% | 82.36% |
Financial Strength
Current Ratio (MRQ)
AMGN
1.31
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
AMGN’s Current Ratio of 1.31 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
THC
1.71
Health Care Providers & Services Industry
- Max
- 2.01
- Q3
- 1.49
- Median
- 1.30
- Q1
- 0.94
- Min
- 0.17
THC’s Current Ratio of 1.71 is in the upper quartile for the Health Care Providers & Services industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
Debt-to-Equity Ratio (MRQ)
AMGN
7.57
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
With a Debt-to-Equity Ratio of 7.57, AMGN operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
THC
3.51
Health Care Providers & Services Industry
- Max
- 2.17
- Q3
- 1.18
- Median
- 0.74
- Q1
- 0.45
- Min
- 0.00
With a Debt-to-Equity Ratio of 3.51, THC operates with exceptionally high leverage compared to the Health Care Providers & Services industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
Interest Coverage Ratio (TTM)
AMGN
2.40
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
AMGN’s Interest Coverage Ratio of 2.40 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
THC
10.27
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.15
- Median
- 5.45
- Q1
- 2.04
- Min
- -4.44
THC’s Interest Coverage Ratio of 10.27 is in the upper quartile for the Health Care Providers & Services industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | AMGN | THC |
|---|---|---|
| Current Ratio (MRQ) | 1.31 | 1.71 |
| Quick Ratio (MRQ) | 0.98 | 1.54 |
| Debt-to-Equity Ratio (MRQ) | 7.57 | 3.51 |
| Interest Coverage Ratio (TTM) | 2.40 | 10.27 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
AMGN
3.06%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
AMGN’s Dividend Yield of 3.06% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.
THC
0.00%
Health Care Providers & Services Industry
- Max
- 5.38%
- Q3
- 2.22%
- Median
- 0.55%
- Q1
- 0.00%
- Min
- 0.00%
THC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
AMGN
82.64%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
At 82.64%, AMGN’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
THC
0.00%
Health Care Providers & Services Industry
- Max
- 186.69%
- Q3
- 74.82%
- Median
- 26.76%
- Q1
- 0.00%
- Min
- 0.00%
THC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | AMGN | THC |
|---|---|---|
| Dividend Yield (TTM) | 3.06% | 0.00% |
| Dividend Payout Ratio (TTM) | 82.64% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
AMGN
24.22
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
AMGN’s P/E Ratio of 24.22 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
THC
10.79
Health Care Providers & Services Industry
- Max
- 55.89
- Q3
- 30.85
- Median
- 21.17
- Q1
- 12.63
- Min
- 0.00
In the lower quartile for the Health Care Providers & Services industry, THC’s P/E Ratio of 10.79 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
AMGN
4.59
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
AMGN’s P/S Ratio of 4.59 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
THC
0.77
Health Care Providers & Services Industry
- Max
- 3.10
- Q3
- 1.74
- Median
- 0.67
- Q1
- 0.24
- Min
- 0.00
THC’s P/S Ratio of 0.77 aligns with the market consensus for the Health Care Providers & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
AMGN
20.21
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
AMGN’s P/B Ratio of 20.21 is in the upper tier for the Biotechnology industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
THC
4.36
Health Care Providers & Services Industry
- Max
- 7.61
- Q3
- 4.32
- Median
- 2.53
- Q1
- 1.14
- Min
- 0.77
THC’s P/B Ratio of 4.36 is in the upper tier for the Health Care Providers & Services industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | AMGN | THC |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 24.22 | 10.79 |
| Price-to-Sales Ratio (TTM) | 4.59 | 0.77 |
| Price-to-Book Ratio (MRQ) | 20.21 | 4.36 |
| Price-to-Free Cash Flow Ratio (TTM) | 14.61 | 7.24 |